TRCT
NUTX

Tower Research Capital (TRC)’s Nutex Health NUTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio NUTX Stock Details NUTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Buy
653
+270
+70% +$34.2K ﹤0.01% 2105
2026
Q1 		$36.4K Buy
383
+143
+60% +$17.5K ﹤0.01% 3018
2025
Q4 		$39.5K Sell
240
-490
-67% -$65K ﹤0.01% 2607
2025
Q3 		$75.4K Buy
730
+578
+380% +$56.7K ﹤0.01% 2223
2025
Q2 		$18.9K Sell
152
-51
-25% -$6.59K ﹤0.01% 3715
2025
Q1 		$9.55K Buy
+203
New +$9.9K ﹤0.01% 3761
2024
Q4 		– Sell
-281
Closed -$6.1K – 5905
2024
Q3 		$6.1K Sell
281
-1,015
-78% -$14.6K ﹤0.01% 4184
2024
Q2 		$7.71K Buy
1,296
+770
+146% +$5.55K ﹤0.01% 4432
2024
Q1 		$7.57K Buy
526
+145
+38% +$2.92K ﹤0.01% 4179
2023
Q4 		$10.3K Buy
+381
New +$11.9K ﹤0.01% 4267
2023
Q3 		– Sell
-238
Closed -$15K – 6146
2023
Q2 		$15K Buy
238
+60
+34% +$5.15K ﹤0.01% 3651
2023
Q1 		$27K Buy
178
+152
+585% +$30.8K ﹤0.01% 3116
2022
Q4 		$7K Sell
26
-15
-37% -$2.88K ﹤0.01% 4593
2022
Q3 		$9K Sell
41
-10
-20% -$4.24K ﹤0.01% 4673
2022
Q2 		$25K Buy
+51
New +$60.1K ﹤0.01% 3567

Other funds holding NUTX

PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WC
Winmill & Co Walpole, New Hampshire $452M AUM 56.84% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return

Tower Research Capital (TRC)'s NUTX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Nutex Health (NUTX) stake by 70% in Q2 2026, buying an estimated $34.2K and bringing the position to 653 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #2105.

Tower Research Capital (TRC) first reported a position in NUTX in Q2 2022 and has held it in 15 quarters since. 154 funds tracked by Wall St. Rank hold NUTX as of Q2 2026.

  • Tower Research Capital (TRC) held 653 shares of Nutex Health worth $112K as of Q2 2026.
  • Tower Research Capital (TRC) bought 270 Nutex Health shares in Q2 2026, an estimated $34.2K.
  • Nutex Health made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2105 holding.
  • Tower Research Capital (TRC) first reported a position in Nutex Health in Q2 2022 and has held it in 15 quarters since.
  • 154 funds tracked by Wall St. Rank held Nutex Health as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.